|
| Thursday, July 1, 2021 |
|
|
Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong |
| Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. more info >> |
|
| Thursday, June 24, 2021 |
|
|
Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401) |
| Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthough Therapy designation for lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of Alzheimer's disease (AD). more info >> |
|
| Wednesday, June 23, 2021 |
|
|
Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Approved In Japan For EZH2 Gene Mutation-positive Follicular Lymphoma |
| Eisai Co., Ltd. announced today that it has obtained manufacturing and marketing approval for the EZH2 inhibitor "Tazverik Tablets 200 mg" (tazemetostat hydrobromide) in Japan with the indication of relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not applicable). more info >> |
|
| Friday, June 18, 2021 |
|
|
Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-202 Antibody Drug Conjugate |
| Eisai Co., Ltd. and Bristol-Myers Squibb Company announced today that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC). more info >> |
|
| Tuesday, June 15, 2021 |
|
|
Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma |
| Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for the antiepileptic agent Zonegran (generic name: zonisamide) in Europe, the Middle East, Russia, and Australia to Advanz Pharma. more info >> |
|
| Wednesday, June 9, 2021 |
|
|
Eisai Receives Special Prize at Platinum Career Award 2021 |
| Eisai Co., Ltd. announced today that it has received a special prize at the Platinum Career Award 2021. The awards ceremony was held via online at the symposium on June 8, 2021. more info >> |
|
|
Eisai To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021) |
| Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021. more info >> |
|
| Tuesday, June 8, 2021 |
|
|
Biogen and Eisai launch initiatives to help patients with Alzheimer's disease access ADUHELM |
| Following U.S. Food and Drug Administration's (FDA) accelerated approval of ADUHELMTM (aducanumab-avwa) as the first and only Alzheimer's disease treatment to address a defining pathology of the diseas. more info >> |
|
|
FDA grants accelerated approval for ADUHELM as the first and only Alzheimer's disease treatment to address a defining pathology of the disease |
| Biogen and Eisai, Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for ADUHELM (aducanumab-avwa) as the first and only Alzheimer's disease treatment to address a defining pathology of the disease by reducing amyloid beta plaques in the brain. more info >> |
|
|
Eisai: New Data on LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus Sunitinib |
| Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. announced new investigational data from the pivotal Phase 3 CLEAR(Study 307)/KEYNOTE-581 trial, which evaluated the combinations of LENVIMA. more info >> |
|
|
|
